Shattuck Labs (STTK)
(Delayed Data from NSDQ)
$1.22 USD
-0.06 (-4.69%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $1.22 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.22 USD
-0.06 (-4.69%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $1.22 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum C VGM
Zacks News
STTK Discontinues Cancer Program, Plans Workforce Cut, Stock Falls
by Zacks Equity Research
Shattuck stock plunges as it discontinues the clinical development of SL-172154 for two blood cancer indications and plans to reduce the workforce by 40%.
Shattuck Labs, Inc. (STTK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Shattuck Labs (STTK) delivered earnings and revenue surprises of -2.44% and 82.84%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Kymera Therapeutics (KYMR) Surges 23.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Kymera Therapeutics (KYMR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Shattuck (STTK) Announces Positive Interim Data on Cancer Drug
by Zacks Equity Research
Shattuck (STTK) will now focus on higher-risk myelodysplastic syndromes and TP53 mutant acute myeloid leukemia indications for lead candidate SL-172154, following encouraging interim data from the phase IB dose expansion study.
After Plunging -19.89% in 4 Weeks, Here's Why the Trend Might Reverse for Shattuck Labs (STTK)
by Zacks Equity Research
Shattuck Labs (STTK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
What Makes Shattuck Labs (STTK) a New Buy Stock
by Zacks Equity Research
Shattuck Labs (STTK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Does Shattuck Labs (STTK) Have the Potential to Rally 34.17% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 34.2% in Shattuck Labs (STTK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Shattuck Labs (STTK) delivered earnings and revenue surprises of 21.28% and 457.50%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 13.25% and 88.33%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Shattuck Labs, Inc. (STTK) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Shattuck Labs, Inc. (STTK) delivered earnings and revenue surprises of 3.85% and 44.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Illumina (ILMN) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Illumina (ILMN) delivered earnings and revenue surprises of 1,500% and 1.11%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -17.12% and 10.52%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Amgen (AMGN) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Amgen (AMGN) delivered earnings and revenue surprises of 12.61% and 5.41%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Shattuck Labs, Inc. (STTK) delivered earnings and revenue surprises of 19.67% and 83.24%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Shattuck Labs, Inc. (STTK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Shattuck Labs, Inc. (STTK), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Should You Buy Shattuck Labs (STTK) Ahead of Earnings?
by Zacks Equity Research
Shattuck Labs (STTK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Earnings Season Could Be Great for Shattuck Labs (STTK)
by Zacks Equity Research
Shattuck Labs (STTK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.